The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Su, Hengchuan ^a   Gu, Yanyun ^a   Li, Fengying ^a   Wang, Qidi ^a   Huang, Baoxing ^a   Jin, Xiaolong ^a   Ning, Guang ^a   Sun, Fukang ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S6; RENIN; VASCULOTROPIN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADRENAL GLAND; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOKALEMIA; IDIOPATHIC DISEASE; IN VITRO STUDY; KIDNEY TUMOR; MALE; MOLECULAR PATHOLOGY; POLYDIPSIA; POLYURIA; PRIMARY HYPERALDOSTERONISM; PROTEIN EXPRESSION; RESISTANT HYPERTENSION; SIGNAL TRANSDUCTION; UPREGULATION; ZONA GLOMERULOSA; CELL LINE; DRUG EFFECTS; HYPERALDOSTERONISM; METABOLISM; MIDDLE AGED; PATHOLOGY; SECRETION (PROCESS);

MAMMALIA;

ADRENAL GLANDS; ADULT; ALDOSTERONE; CELL LINE; CELL PROLIFERATION; FEMALE; HUMANS; HYPERALDOSTERONISM; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84876565461     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062399     Document Type: Article

References (19)

1. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, et al. (2005) Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 16: 114-119.
2. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, et al. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89: 1045-1050.
3. Stowasser M, Gordon RD, Gunaekera TG, Cowley DC, Ward G, et al. (2003) High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens 21: 2149-2157.
4. Guertin DA, Sabatini DM, (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
5. Konings IR, Verweij J, Wiemer EA, Sleijfer S, (2009) The applicability of mTOR inhibition in solid tumors. Curr Cancer Drug Targets 9: 439-450.
6. Hanna SC, Heathcote SA, Kim WY, (2008) mTOR pathway in renal cell carcinoma. Expert Rev Anticancer Ther 8: 283-292.
7. De Martino MC, van Koetsveld PM, Pivonello R, Hofland LJ, (2010) Role of the mTOR pathway in normal and tumoral adrenal cells. Neuroendocrinology 92 (Suppl 1):: 28-34.
8. Brizuela L, Rábano M, Gangoiti P, Narbona N, Macarulla JM, et al. (2007) Sphingosine-1-phosphate stimulates aldosterone secretion through a mechanism involving the PI3K/PKB and MEK/ERK 1/2 pathways. J Lipid Res 48: 2264-2274.
9. Williams TA, Monticone S, Morello F, Liew CC, Mengozzi G, et al. (2010) Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro. Hypertension 55: 1468-1475.
10. Mulatero P, Bertello C, Rossato D, Mengozzi G, Milan A, et al. (2008) Roles of clinical criteria, computed tomography scan, and adrenal vein sampling in differential diagnosis of primary aldosteronism subtypes. J Clin Endocrinol Metab 93: 1366-1371.
11. Liu P, Cheng H, Roberts TM, Zhao JJ, (2009) Target-ing the phosphoinositide 3-kinase pathway in cancer. Nat Rev 8: 627-644.
12. Kimura R, Okouchi M, Fujioka H, Ichi-yanagi A, Ryuge F, et al. (2009) Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 162: 1212-1219.
13. Takekoshi K, Isobe K, Yashiro T, Hara H, Ishii K, et al. (2004) Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci 74: 863-871.
14. Rainey WE, Saner K, Schimmer B P, (2004) Adrenocortical cell lines. Mol Cell Endocrinol 228: 23-38.
15. Lichtenauer UD, Shapiro I, Osswald A, Meurer S, Kulle A, et al. (2012) Characterization of NCI-H295R Cells as an In Vitro Model of Hyperaldosteronism. Horm Metab Res. Epub ahead of print.
16. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, et al. (2010) Regulation of Insulin-like Growth Factor-Mammalian Target of Rapamycin Signaling by MicroRNA in Childhood Adrenocortical Tumors. Cancer Res 70: 4666-4675.
17. Mariniello B, Rosato A, Zuccolotto G, Rubin B, Cicala MV, et al. (2012) Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocr Relat Cancer 19: 527-539.
18. Bakan I, Laplante M, (2012) Connecting mTORC1 signaling to SREBP-1 activation. Curr Opin Lipidol 23: 226-234.
19. Régimbald-Dumas Y, Frégeau MO, Guillemette G, (2011) Mammalian target of rapamycin (mTOR) phosphorylates inositol 1,4,5-trisphosphate receptor type 2 and increases its Ca(2+) release activity. Cell Signal 23: 71-79.